

HGCO19-Vaccine Trial at ICMR-NICED: Request for participation

ICMR-NICED, a premier research organisation, under the Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, is going to initiate a CDSCO approved regulatory trial entitled “A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects”. ICMR-NICED will be a part of Phase-III study. The primary objective of the study is to assess the safety, reactogenicity, tolerability and immunogenicity of the novel corona vaccine candidate-HGCO-19, in healthy adult subjects following two doses administered 28 days apart. The COVISHIELD™ will be used as a comparator vaccine in Phase III study. Participants of any gender of aged 18 years and above residing preferably in Kolkata (within 10 kms. of ICMR-NICED) are encouraged to participate voluntarily in this trial. Willing participants are requested to contact in this number (**9903824322**) or email (HGCO19niced@gmail.com) their personal details (name, age, sex, address, contact number, email and comorbidities, if any) for further information. Limited number of participants will be enrolled in the study and they will be screened for eligibility criteria before enrolment in the study. The participant enrolment will continue till the target is achieved.

Study site: ICMR-National Institute of Cholera & Enteric Diseases, P-33, CIT, Road, Scheme-XM, Beliaghata, Kolkata – 700010

Kindly send your willingness to participate through e-mail in the following format:

Sl. No.	Name	Gender	Age	Address	Contact No	Email	Comorbidities